Boston Scientific has obtained US Food and Drug Administration (FDA) and CE mark approval for its CoverEdge 32 and CoverEdge X 32 Surgical Leads, which will be used in the treatment of spinal cord pain.
Featuring Illumina 3D Software, the CoverEdge Surgical Leads have been developed for use with the Precision Spectra Spinal Cord Stimulator (SCS) System.
Boston Scientific neuromodulation president Maulik Nanavaty said: "The new CoverEdge Surgical Leads allow surgeons to utilize the full potential of our innovative Precision Spectra SCS System and offer their patients an opportunity for excellent pain relief.
"The introduction of the Precision Spectra System in 2013 has changed the way many physicians treat their patients with chronic pain."
According to the company, CoverEdge Surgical Leads offers 32 contacts, and helps to deliver more focused coverage of the spinal cord for more pain relief, while previous surgical leads have delivered pain therapy with a maximum of 16 independent contacts.
The company plans to introduce CoverEdge Surgical Leads at the Congress of Neurological Surgeons (CNS) in this week in Boston.
Boston Scientific said that it launched the world’s first rechargeable SCS device, the Precision System, in 2004, which was also the first 16-contact implantable SCS device.
Image: Boston Scientific’s Corporate Headquarters in Marlborough, Massachusetts. Photo: courtesy of Boston Scientific Corporation.